GlassScriptPhysician profile
Michael J Roggelin
NPI 1528520756
$20,628.66
in general payments reported to CMS, 2019-2025
24 companies · $5,530 in 2025
The $5,530 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,578 · 2022: $1,694 · 2023: $2,361 · 2024: $9,467 · 2025: $5,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,750 · Food and Beverage: $6,182 · Travel and Lodging: $1,415 · Education: $10.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,750.00 |
| Food and Beverage | $6,181.58 |
| Travel and Lodging | $1,414.72 |
| Education | $10.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $14,929.61 | 2021-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $2,582.56 | 2021-2025 | Biktarvy |
| Theratechnologies INC. | $721.05 | 2021-2025 | Egrifta, Trogarzo |
| Abbvie INC. | $671.16 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $545.88 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Napo Pharmaceuticals INC | $273.90 | 2021-2024 | Mytesi |
| Janssen Biotech, INC. | $205.03 | 2021-2023 | Symtuza |
| Emd Serono, INC. | $154.48 | 2021-2025 | Serostim |
| Janssen Products, LP | $99.00 | 2022 | |
| Antares Pharma, INC. | $67.09 | 2022 | |
| Tolmar, INC. | $54.55 | 2024-2025 | Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $50.99 | 2024-2025 | |
| Exact Sciences Corporation | $39.43 | 2024-2025 | Cologuard Collection Kit |
| Janssen Scientific Affairs, LLC | $35.44 | 2023 | Symtuza |
| Verity Pharmaceuticals INC. | $34.00 | 2025 | Tlando |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $26.83 | 2022 | |
| Glaxosmithkline, LLC. | $26.63 | 2025 | Shingrix |
| Otsuka America Pharmaceutical, INC. | $21.21 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.88 | 2025 | Xifaxan |
| Phadia US INC. | $18.58 | 2024 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $14.95 | 2021 | |
| Amgen INC. | $14.02 | 2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $12.65 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Roggelin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.